Careers
Press Releases
Newsroom
Investor Relations
Privacy Policy
Site Directory
Terms & Conditions
| The world’s leader in diagnostic |
|
|
|
|
|
|
IGRAs in the Diagnosis of Tuberculosis
Upcoming Webinar: September 9th, 2010 at 1:00 pm EDT
Audience: clinical healthcare providers and laboratory professionals
Click here for more info on this program, focused on current guidelines and clinical use of interferon gamma release assays (IGRAs).
Click here to register for this Webinar.
New Pregnancy Health Reminder Service
Stay informed about important lab tests and learn helpful tips related to your pregnancy. Read more >
Quest Diagnostics has received CEO Cancer Gold Standard™ accreditation, recognizing our commitment in the fight against cancer, beginning with our efforts at improving the health and wellness of our own employees. Read more >
AccuType™ CP
Physicians: Learn about a new test that may help you determine your patient's response to PLAVIX® (clopidrogel bisulfate).
Learn about Quest Diagnostics' testing services for ovarian and cervical cancers — including the new FDA-cleared OVA1™ test.
Find out how adopting Care360 today can prepare your practice for tomorrow. Our modular system enables you to take a step-wise approach to technology adoption.
HEALTH TESTING YOU CHOOSE™ - Get an assessment of your personal health based on laboratory tests and diagnostic test kits that you can order directly online. You can have the results of the tests that you register for made available to you via the web or via other electronically retrievable means, or have printed reports mailed to you.
New York State Approves Quest Diagnostics’ Fragile X Syndrome Test
| - | XSense® is the first laboratory test that may be suitable for population-based screening for Fragile X Syndrome, the leading inherited cause of mental retardation |
Quest Diagnostics Reports Second Quarter 2010 Financial Results; Updates Guidance For 2010
| - | Diluted earnings per share of $1.07, 7% above 2009 |
| - | Revenues of $1.9 billion, 1.4% below 2009 |
| - | Full year EPS expected to be between $3.90 and $4.00; full year revenues expected to be approximately 1% below prior year |
| - | Listen to a replay of Quest Diagnostics' Second Quarter Conference Call |
| - | Read a Transcript of Company Prepared Comments |
First FDA Clearance of a 2009 H1N1 Test Given to Quest Diagnostics’ Focus Diagnostics Business
| - | Simplexa™ molecular RT-PCR test runs on the 3M Integrated Cycler |
H1N1 Crowds Out Other Flu Viruses, Higher Positive Trends in Children Tested
| - | The Quest Diagnostics Health Trends™ Report analyzes 195,000 H1N1 test results performed nationally since May 2009 |
Quest Diagnostics Reports First Quarter 2010 Financial Results; Updates Guidance for 2010
| - | Diluted earnings per share of $0.89, and revenues of $1.8 billion, unchanged from 2009 |
| - | 2010 adjusted EPS guidance unchanged at between $4.10 and $4.30 |
| - | On a reported basis, 2010 EPS guidance is expected to be between $4.00 and $4.20 |
| - | Listen to a replay of Quest Diagnostics' First Quarter Conference Call |
| - | Read a Transcript of Company Prepared Comments |
Quest Diagnostics Honored by CEO Roundtable on Cancer
| - | Company Granted CEO Gold Standard™ Accreditation for Its Commitment to Employee Health and the Fight Against Cancer |
OVA1 Blood Test Now Available to Aid Pre-surgical Evaluation of Women for Ovarian Cancer
| - | FDA-cleared test helps direct women to the most appropriate surgeon, promoting better outcomes |
| - | Company also ranked among top 100 Best Corporate Citizens by Corporate Responsibility Magazine |
Quest Diagnostics Unveils Care360™ EHR
| - | Company Empowers Physicians to Embrace Digital Healthcare, Connect with Peers, and Work Toward Meaningful Use One Step at a Time |
| - | 90-Day Free Trial for Web-based Care360 EHR and Care360 ePrescribing Introduced at HIMSS10 |